CDDO-Im

CAT: 0804-HY-15725-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-15725-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
CDDO-Im (RTA-403) is an activator of Nrf2 and PPAR, with Kis of 232 and 344 nM for PPARα and PPARγ[1][2].
CAS Number
[443104-02-7]
Product Name Alternative
RTA-403; TP-235; CDDO-Imidazolide
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Ferroptosis; Keap1-Nrf2; PPAR
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; NF-ĪŗB; Vitamin D Related/Nuclear Receptor
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/CDDO-Im.html
Purity
99.30
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
CC(C)([C@]1([H])CC[C@@]([C@@]2(CC[C@]3(CCC(C)(C[C@@]3([H])[C@]24[H])C)C(N5C=CN=C5)=O)C)6C)C(C(C#N)=C[C@]1(C)C6=CC4=O)=O
Molecular Formula
C34H43N3O3
Molecular Weight
541.72
Precautions
H302, H315, H319, H335
References & Citations
[1]Place AE, et al. The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res. 2003 Jul;9 (7) :2798-806.|[2]Liby K, et al. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res. 2005 Jun 1;65 (11) :4789-98.|[3]So JY, et al. A synthetic triterpenoid CDDO-Im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer. PLoS One. 2014 Sep 17;9 (9) :e107616.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PPARα; PPARγ

Popular Products